KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.

Robin Myte, Andrea Mattsson, Matt Poole, Dustin J Little, Per Nyström, Alasdair Henderson, Brian L Claggett, Samvel B Gasparyan, Scott D Solomon, John J V McMurray

Circ Heart Fail 18(12) e013496

PMID41170566
PMCIDPMC12704667
DOI10.1161/CIRCHEARTFAILURE.125.013496
发表日期2025-10-31
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Patients with cardiovascular conditions like heart failure (HF) often exhibit significant heterogeneity of the risk of clinical events. In clinical trials, large risk heterogeneity can result in an underestimation of treatment effects derived from Cox proportional hazards models. This occurs due to selection bias when estimating the hazard ratio, stemming from a disproportionate reduction of event-free patients in the control group compared with an effective active group over time, ultimately reducing the statistical power. Therefore, it is important to explore alternative analysis methods for outcome trials that are robust with respect to risk heterogeneity. METHODS: We used clinical data from 2 dapagliflozin HF trials-DAPA-HF (Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction) and DELIVER (Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction) to characterize the extent of risk heterogeneity and nonproportionality of hazards in HF. We then evaluated a candidate method for estimating treatment effects in HF outcome trials, namely the survival proportional odds model, and compared this to traditional Cox regression in a simulation study. RESULTS: In the dapagliflozin trials, nonproportional hazards were a larger issue in the HFpEF population of the DELIVER trial compared with the more homogeneous heart failure with reduced ejection fraction population of the DAPA-HF trial. In simulations of populations with varying degrees of heterogeneity, the survival proportional odds model was more robust to heterogeneity and demonstrated higher power compared with traditional Cox regression in high heterogeneity populations, while performing similarly or slightly worse in more or less heterogeneous populations. Reanalyses of the dapagliflozin trials confirmed these findings, with the survival proportional odds model providing consistently higher power in the DELIVER trial and similar power in the DAPA-HF trial. CONCLUSIONS: In HF trials, the survival proportional odds model is a viable and more robust alternative for analyzing time to event outcomes, also providing an intuitive interpretation of the treatment effect directly linked to survival probability: improved odds of being event-free in the active group compared with the control group. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT03036124 and NCT03619213.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2. Kaplan-Meier curves for time to first worsening of heart failure or cardiovascular (CV) death in the DAPA-HF (Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction) and DELIVER (Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction) trials with fitted parametric models overlaid. A , Models fitted in both arms together (assuming proportional hazards). B , Models fitted separately in each arm (not assuming proportional hazards). Dapa indicates dapagliflozin; HFpEF, heart failure with preserved ejection fraction; and HFrEF; heart failure with reduced ejection fraction.

DELIVER_HFpEF_

time to first worsening of heart failure or cardiovascular (CV) death

Figure 2 · Panel DELIVER_HFpEF_

quality_warning 待 EXE 对齐 预期 5 条 已提取 1 条

Panel DELIVER_HFpEF_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 5 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
DAPA-HF_HFrEF_

time to first worsening of heart failure or cardiovascular (CV) death

Figure 2 · Panel DAPA-HF_HFrEF_

quality_warning 待 EXE 对齐 预期 5 条 已提取 2 条

Panel DAPA-HF_HFrEF_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 5 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
DELIVER_HFpEF__3

time to first worsening of heart failure or cardiovascular (CV) death

Figure 2 · Panel DELIVER_HFpEF__3

quality_warning 待 EXE 对齐 预期 5 条 已提取 1 条

Panel DELIVER_HFpEF__3 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 5 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
DAPA-HF_HFrEF__4

time to first worsening of heart failure or cardiovascular (CV) death

Figure 2 · Panel DAPA-HF_HFrEF__4

quality_warning 待 EXE 对齐 预期 5 条 已提取 2 条

Panel DAPA-HF_HFrEF__4 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 5 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Illustration of survival odds as an efficacy summary measure in a clinical trial. Survival odds are directly tied to survival probabilities, typically estimated with the Kaplan-Meier method, and reflect the odds of being event-free by a given time point. In contrast, hazard represents the risk of an event among patients still event-free at each moment; this concept is more abstract, is only indirectly related to survival curves, and differences in patient risk at randomization lead to a selection of less sick patients over time, which can bias comparisons between groups. HR indicates hazard ratio; and SOR, survival odds ratio.
非 KM Figure
Figure 3Figure 3. Cumulative incidence by treatment group in simulated heart failure trial scenarios. True cumulative incidence curves are shown for each treatment group across 4 simulation scenarios reflecting varying degrees of risk heterogeneity, based on event times from Weibull distributions.
非 KM Figure
Figure 4Figure 4. Power analysis based on simulations by scenario of risk heterogeneity. Based on 1000 simulated 1:1 randomized trials with given N, 3-year follow-up, and true event rates shown in Figure 3. Power for 1-sided alpha=0.025. Cox indicates Cox regression; and SPOM, survival proportional odds model.
非 KM Figure
Figure 5Figure 5. Power analysis based on resampling real trials DAPA-HF (Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction) and DELIVER (Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction). Power for 1-sided alpha=0.025 based on 1000 bootstrap resampling of the trials. Cox indicates Cox regression; and SPOM, survival proportional odds model.
非 KM Figure